Global Standardization of Lipid/Lipoprotein Testing.

As lipid/lipoprotein research elucidated the mechanism of atherosclerosis, lipid/lipoprotein tests were developed for simple and rapid screening, diagnosis, and management of dyslipidemic patients. In 1988, the Centers of Disease Control and Prevention (CDC) in the United States initiated a global standardization program for lipid/lipoprotein testing through the Cholesterol Reference Measurement Laboratory Network (CRMLN), in which the chemical lipid measurements were adopted as reference measurement procedures (RMPs). In 2010, an American group questioned the accuracy of the direct LDL-C and HDL-C assays, causing a great deal of confusion.

Harmonization of Lipoprotein(a) Immunoassays Using A Serum Panel Value Assigned with The IFCC-Endorsed Mass Spectrometry-Based Reference Measurement Procedure as A First Step Towards Apolipoprotein Standardization.

Aim: Lipoprotein (a) [Lp(a)] is a well-established risk factor for cardiovascular disease independent of low-density lipoprotein-cholesterol (LDL-C). The Lp(a) concentrations were inconsistent between the immunoassays. This study aimed to investigate whether harmonization of Lp(a) measurements can be achieved using a serum panel value assigned with the IFCC-endorsed mass spectrometry-based reference measurement procedure (IFCC-MS-RMP).

Carvedilol suppresses ryanodine receptor-dependent Ca2+ bursts in human neurons bearing PSEN1 variants found in early onset Alzheimer's disease.

Seizures are increasingly being recognized as the hallmark of Alzheimer's disease (AD). Neuronal hyperactivity can be a consequence of neuronal damage caused by abnormal amyloid β (Aß) depositions. However, it can also be a cell-autonomous phenomenon causing AD by Aß-independent mechanisms.

Antimicrobial susceptibility analysis of isepamicin combination treatments in species.

This study evaluated the antimicrobial potency of the combination of isepamicin (ISP) for species (MABS). 34 clinical MABS strains were isolated from clinical samples. Of them, 11 (32.

Multidrug-resistant Klebsiella pneumoniae clinical isolates producing NDM- and OXA-type carbapenemase in Nepal.

Objectives: The emergence of multidrug-resistant Klebsiella pneumoniae has become a serious problem in medical settings worldwide.

Methods: A total of 46 isolates of multidrug-resistant K. pneumoniae were obtained from 2 hospitals in Nepal from October 2018 to April 2019.